Skip to main content
SpringerLink
Log in

Comment on: “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal”

  • Letter to the Editor
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ramaekers BL, Riemsma R, Tomini F, et al. Abiraterone acetate for the treatment of chemotherapy-naive metastatic castration-resistant prostate cancer: an evidence review group perspective of an NICE single technology appraisal. Pharmacoeconomics. 2017;35(2):191–202. doi:10.1007/s40273-016-0445-5.

    Article  PubMed  Google Scholar 

  2. National Institute for Health and Care Excellence. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: technology appraisal guidance [TA387]. Published date: 27 Apr 2016. Last updated: 27 July 2016. https://www.nice.org.uk/guidance/ta387. Accessed 6 Dec 2016.

  3. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60. doi:10.1016/S1470-2045(14)71205-7.

    Article  CAS  PubMed  Google Scholar 

  4. National Institute for Health and Care Excellence. Chapter 4: evidence and interpretation. Cost-effectiveness section 4.12. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal guidance [TA375]. Published date: 26 Jan 2016. https://www.nice.org.uk/guidance/ta375/chapter/4-Evidence-and-interpretation#cost-effectiveness. Accessed 6 Dec 2016.

  5. Sorensen S, Hall F, Reifsnider O, et al. Modeling treatments and outcomes in metastatic castration-resistant prostate cancer: a case study of discrete event simulation and the challenges for a UK NICE evaluation. Presented at the ISPOR 19th Annual European Congress; 29 Oct–2 Nov 2016; Vienna. http://www.valueinhealthjournal.com/article/S1098-3015(16)33577-X/abstract. Accessed 15 Mar 2017. [Value Health. 2016;19(7):A733, abstract PCN137].

  6. Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics. 2013;31(8):663–75. doi:10.1007/s40273-013-0064-3.

    Article  PubMed  Google Scholar 

  7. Joulain F, Proskorovsky I, Allegra C, et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer. 2013;109(7):1735–43. doi:10.1038/bjc.2013.523.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Muszbek N, Kreif N, Valderrama A, et al. Modelling survival in hepatocellular carcinoma. Curr Med Res Opin. 2012;28(7):1141–53. doi:10.1185/03007995.2012.691422.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA

    Odette Reifsnider & Sonja Sorensen

  2. Janssen-Cilag Limited, High Wycombe, Buckinghamshire, UK

    Fiona Hall, Isabelle Girod & Jennifer Lee

  3. Evidera, Montreal, QC, Canada

    Irina Proskorovsky

Authors
  1. Odette Reifsnider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fiona Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonja Sorensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irina Proskorovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isabelle Girod
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jennifer Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonja Sorensen.

Ethics declarations

Funding

This analysis was sponsored and funded by Janssen-Cilag Limited.

Conflict of interest

Fiona Hall, Isabelle Girod, and Jennifer Lee are employees of Janssen-Cilag Limited. Sonja Sorensen, Odette Reifsnider, and Irina Proskorovsky are salaried employees of Evidera, a biopharmaceutical research and consulting firm. They are not allowed to accept remuneration of any sort from Evidera clients. Evidera received funding from Janssen-Cilag Limited.

Additional information

A response to this letter has been invited. This letter comments on https://link.springer.com/article/10.1007/s40273-016-0445-5.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reifsnider, O., Hall, F., Sorensen, S. et al. Comment on: “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal”. PharmacoEconomics 35, 661–663 (2017). https://doi.org/10.1007/s40273-017-0502-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-017-0502-8

Search

Navigation